Clinical Trial: Furmonertinib Combined With Intrathecal Chemotherapy and Stereotactic Radiotherapy (SRT) for EGFR-Mutated NSCLC Patients With Brain Parenchymal and Leptomeningeal Metastases

U.S., Dec. 27 -- ClinicalTrials.gov registry received information related to the study (NCT07304739) titled 'Furmonertinib Combined With Intrathecal Chemotherapy and Stereotactic Radiotherapy (SRT) for EGFR-Mutated NSCLC Patients With Brain Parenchymal and Leptomeningeal Metastases' on Sept. 23.

Brief Summary: A Single-Arm Clinical Study of Furmonertinib (160mg) Combined with Intrathecal Chemotherapy (ITC) and Stereotactic Radiotherapy (SRT) as First-Line Treatment in EGFR Classic Mutation-Positive NSCLC Patients with Brain Parenchymal and Leptomeningeal Metastases

Study Start Date: Dec. 22

Study Type: INTERVENTIONAL

Condition: Non Small Cell Lung Cancer

Intervention: DRUG: Furmonertinib

Furmonertinib: 160mg, once daily, orally.

DR...